Navigation Links
Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
Date:4/16/2009

First Quarter 2009 Financial Results

VANCOUVER, April 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing its financial results for the first quarter ended March 31, 2009, on Thursday April 30, 2009 at 11:00 AM ET (8:00 AM Pacific).

    Dial-in information for the earnings call on April 30, 2009 is as
    follows:
    North America (toll-free): (800) 901-5247
    International: (617) 786-4501
    Enter Passcode: 72734002

A live webcast of the earnings call will be available to interested parties through Angiotech's website at www.angiotech.com in the Investor Relations section.

A press release announcing Angiotech's financial results will be issued prior to the call on April 30 at approximately 8:00 AM ET (5:00 AM Pacific).

An archived replay of the call will be available until May 7, 2009.

    Replay information is as follows:
    North America (toll-free): (888) 286-8010
    International: (617) 801-6888
    Enter Passcode: 95526962

    About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
2. Angiotech announces positive results from Bio-Seal(TM) clinical study
3. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
4. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
5. Angiotech Pharmaceuticals announces time change of conference call and webcast
6. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
7. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
8. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
9. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
10. Angiotech wins before the UK House of Lords
11. Angiotech to Establish Separate Operating and Royalty Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
(Date:9/30/2014)... a bio-mimicking analog of one of nature,s most ... research team led by Alejandro Briseno of the ... step in developing long-sought polymer architecture to boost ... in electronic devices. , Briseno, with colleagues ... at Stanford University and Dresden University of Technology, ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Jan. 31, 2012  Argos Therapeutics Inc., today announced ... analysis of AGS-003-006, a Phase 2 study of ... in patients with advanced renal cell carcinoma (RCC). ... anti-tumor memory T cell responses and overall survival. ...
... 2012   Veracyte, Inc ., a molecular diagnostics company ... the appointment of Mark Spring as chief financial officer. ... has joined the Veracyte team," said Bonnie Anderson, Veracyte,s ... a CFO and senior finance leader in both public ...
... Life Technologies Corporation (NASDAQ: LIFE ) ... the following upcoming investment conferences in February. ... present at the Leerink Swann 2012 Global Healthcare Conference ... Life Technologies will also present at the 2012 ...
Cached Biology Technology:Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3Life Technologies to Present at Upcoming Investment Conferences in February 2
(Date:9/30/2014)... Fish can live in almost any aquatic environment on ... up many species are pushed to the limit. The ... could prove critical for how different species cope in ... the University of Gothenburg, published in the scientific journal ... Climate change continues apace thanks to increasing levels of ...
(Date:9/30/2014)... N.C. -- Pollution in urban and farm runoff in ... new study finds. , The study, published Tuesday ... that nitrogen in the runoff ends up in algae ... on the animals, eyes, flippers and internal organs. , ... the National Oceanic and Atmospheric Administration (NOAA) conducted the ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... has been a well-kept secret of our immune system,s success. The ... Cell Press publication, offer an explanation for how specialized immune cells ... in the process. The focus of the study is a ... a pore in cells targeted for destruction. With that pore in ...
... uncovered a new role for a key cancer protein, a ... of a variety of tumors. Many cancers are driven ... the cells to escape growth controls and proliferate abnormally. In ... Nature , researchers discovered that cyclin D1 also helps ...
... Evidence from benchmark sites across the ... allows for land-use sharing in agriculture, forests and other ... gas emissions and raising food production levels. It provides ... land for forests through agricultural intensification. Agricultural intensification, also ...
Cached Biology News:How killer immune cells avoid killing themselves 2Cancer protein discovery may aid radiation therapy 2Cancer protein discovery may aid radiation therapy 3Integrating agriculture and forestry in the landscape is key to REDD 2
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
MMP-1/8 (H-300)...
... contains choice of Printing Surface (3 glass slides coated ... layer, 1 silicon wafer coated with 1000 Angstroms of ... slides) and PDMS Stamps (3 PDMS micropatterned stamps with ... um x 10 mm or 200 um x 10 ...
Biology Products: